Pharmaceutical Business review

Soar BioDynamics introduces new screening tool for prostate cancer

According to the company, Soar Dynamic Screening demonstrates a new approach to healthcare by providing men a detailed analysis of their prostate health based on several factors beyond the industry-standard prostate-specific antigen (PSA) test. The tool also analyzes other important variables including a man’s personal health history, PSA trends over time and comparisons with up to a million case studies.

Soar Dynamic Screening for the prostate uses individual profile data, test results and cutting-edge technology to deliver personalized analysis, the company noted.

Through a web-based tool, men enter the results of their PSA test history and personal information such as height, weight and health history. This information is compared with up to a million case studies and outcomes from other men with various prostate conditions. Finally, the system may suggest a medical detective process for doctors and their patients in their efforts to detect non-cancerous prostate conditions and improve prostate cancer screening, the company said.

Soar provides men with 20 opportunities annually to analyze their prostate health data, enabling ongoing, up-to-date analyses when needed to support men and their doctors’ efforts to conduct medical detective processes. Soar does not collect personally identifiable information, maximizing patient privacy, the company added.

Exit mobile version